Parabolan 100 - Canada Peptides

Trenbolone hexahydrobenzylcarbonate, marketed as Parabolan, was the only form of trenbolone ever approved for human use. Developed by Negma Laboratoires in France, it was introduced after early studies on long-acting esters by Roussel-UCLAF in 1967. Unlike its faster-acting acetate counterpart used in veterinary medicine, this ester allowed for biweekly injection and was prescribed for conditions like muscle wasting and osteoporosis. Its production ended in 1997, marking the close of pharmaceutical-grade human trenbolone availability.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Parabolan 100 by Canada Peptides, consult with your doctor or healthcare professional.